How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Mezagitamab Stablized eGFR 18 Months After Treatment in IgAN
Phase 1b IgAN data: mezagitamab (TAK‑079) stabilized eGFR, reduced proteinuria and serum Gd-IgA1, no serious AEs through Week 96; Phase 3 trials enrolling.
www.takeda.com
November 11, 2025 at 3:25 PM
How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Research presented at #KidneyWk examined the association between circulating inflammatory proteins and disease progression in #IgAN. #nephrology #iganephropathy #nephsky
Identifying Biomarkers for Disease Progression in IgA Nephropathy | Docwire News
A study examined the association between circulating inflammatory proteins and disease progression in IgA nephropathy (IgAN).
buff.ly
December 12, 2024 at 3:20 PM
Research presented at #KidneyWk examined the association between circulating inflammatory proteins and disease progression in #IgAN. #nephrology #iganephropathy #nephsky
Even when levels are below the current KDIGO threshold, #proteinuria indicates a risk of kidney failure. #kidneywk #iganephropathy #igan #kidneydisease #nephsky
Population and Proteinuria Comparison Between UK and Chinese IgAN Patients | Docwire News
Even when levels are below the current KDIGO threshold, proteinuria in IgA nephropathy (IgAN) indicates a risk of kidney failure.
buff.ly
December 6, 2024 at 10:01 PM
Even when levels are below the current KDIGO threshold, #proteinuria indicates a risk of kidney failure. #kidneywk #iganephropathy #igan #kidneydisease #nephsky
Researchers evaluated the association between urinary sodium excretion and kidney disease progression events. #kidneydisease #iganephropathy #urinarysodium
Association of Urinary Sodium Excretion With IgAN Progression | Docwire News
Researchers examined the role of urinary sodium excretion and the progression of IgA nephropathy (IgAN).
buff.ly
December 31, 2024 at 7:00 PM
Researchers evaluated the association between urinary sodium excretion and kidney disease progression events. #kidneydisease #iganephropathy #urinarysodium
I didn't do anything for #worldkidneyday because my #kidneystory changed again. A gentle reminder to EVERYONE that #kidneydisease is life long and a #kidneytransplant is a treatment not a cure. #IGANephropathy #hemodialysis #nhswales #cardiff @kidneycareuk.bsky.social
March 26, 2025 at 11:12 AM
I didn't do anything for #worldkidneyday because my #kidneystory changed again. A gentle reminder to EVERYONE that #kidneydisease is life long and a #kidneytransplant is a treatment not a cure. #IGANephropathy #hemodialysis #nhswales #cardiff @kidneycareuk.bsky.social
I finally got approved for Fabhalta (iptacopan)! I’m not naive enough to think this will be a miracle drug, but I am hopeful that it will at least slow the progression of my #IGAnephropathy.
December 2, 2024 at 4:57 PM
I finally got approved for Fabhalta (iptacopan)! I’m not naive enough to think this will be a miracle drug, but I am hopeful that it will at least slow the progression of my #IGAnephropathy.
MORE NEWS from #KidneyWk: ETA selective antagonist SC0062 showed a clinically meaningful reduction in proteinuria in patients with #IgAN. #iganephropathy #nephrology #kidneydisease #nephsky
SC0062 Effective and Safe in Patients With IgA Nephropathy | Docwire News
Novel endothelin receptor type A (ETA) selective antagonist SC0062 showed a clinically meaningful reduction in proteinuria in patients with IgA nephropathy (IgAN).
buff.ly
December 3, 2024 at 6:30 PM
MORE NEWS from #KidneyWk: ETA selective antagonist SC0062 showed a clinically meaningful reduction in proteinuria in patients with #IgAN. #iganephropathy #nephrology #kidneydisease #nephsky
B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy
doi.org/10.1016/j.kint.2025.03.019
#OpenAccess #MedSky #NephSky #SkyNeph #IgAN #IgAnephropathy
doi.org/10.1016/j.kint.2025.03.019
#OpenAccess #MedSky #NephSky #SkyNeph #IgAN #IgAnephropathy
April 28, 2025 at 4:29 PM
B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy
doi.org/10.1016/j.kint.2025.03.019
#OpenAccess #MedSky #NephSky #SkyNeph #IgAN #IgAnephropathy
doi.org/10.1016/j.kint.2025.03.019
#OpenAccess #MedSky #NephSky #SkyNeph #IgAN #IgAnephropathy
VISIONARY is the largest phase 3 trial of an #IgAN treatment to date and is intended to evaluate the efficacy and safety of sibeprenlimab. #iganephropathy #kidney #nephrology #NKFClinicals #nephsky www.docwirenews.com/post/baselin...
Baseline Characteristics in VISIONARY Trial of Sibeprenlimab | Docwire News
At SCM25, researchers presented baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy (IgAN).
www.docwirenews.com
May 2, 2025 at 6:03 PM
VISIONARY is the largest phase 3 trial of an #IgAN treatment to date and is intended to evaluate the efficacy and safety of sibeprenlimab. #iganephropathy #kidney #nephrology #NKFClinicals #nephsky www.docwirenews.com/post/baselin...
This is very good news. Can't wait to see what they report from the second clinical endpoint down the road.
#nephrology #iganephropathy #igan #kidneys
#nephrology #iganephropathy #igan #kidneys
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy｜News Releases | Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd News Releases
www.otsuka.co.jp
April 1, 2025 at 6:25 PM
This is very good news. Can't wait to see what they report from the second clinical endpoint down the road.
#nephrology #iganephropathy #igan #kidneys
#nephrology #iganephropathy #igan #kidneys
TANGO study and it's ongoing projects #FSGS #IgAnephropathy #membranousnephropathy #complementmediatedGN transplant centres are urged to join @LVRiella
March 28, 2025 at 3:40 AM
TANGO study and it's ongoing projects #FSGS #IgAnephropathy #membranousnephropathy #complementmediatedGN transplant centres are urged to join @LVRiella
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab in the treatment of IgA nephropathy. #igan #iganephropathy #nephsky #nephrology #kidneydisease
Otsuka Seeks FDA License for Sibeprenlimab in IgAN | Docwire News
Otsuka filed a Biologics License Application with the FDA for the monoclonal antibody sibeprenlimab for the treatment of IgA nephropathy (IgAN).
www.docwirenews.com
April 1, 2025 at 6:35 PM
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab in the treatment of IgA nephropathy. #igan #iganephropathy #nephsky #nephrology #kidneydisease
Key points:
+ Stable eGFR at week 96 (+2.5 mL/min/1.73 m²)
+ Gd-IgA1 production down 50% at week 96
+ Proteinuria (UPCR) reduced by 55.2% at week 96
This is at week 96, 18 *months* after treatment was discontinued at week 24. #NephSky #KidneyWk #IgAN #IgANephropathy
+ Stable eGFR at week 96 (+2.5 mL/min/1.73 m²)
+ Gd-IgA1 production down 50% at week 96
+ Proteinuria (UPCR) reduced by 55.2% at week 96
This is at week 96, 18 *months* after treatment was discontinued at week 24. #NephSky #KidneyWk #IgAN #IgANephropathy
November 11, 2025 at 4:34 PM
Key points:
+ Stable eGFR at week 96 (+2.5 mL/min/1.73 m²)
+ Gd-IgA1 production down 50% at week 96
+ Proteinuria (UPCR) reduced by 55.2% at week 96
This is at week 96, 18 *months* after treatment was discontinued at week 24. #NephSky #KidneyWk #IgAN #IgANephropathy
+ Stable eGFR at week 96 (+2.5 mL/min/1.73 m²)
+ Gd-IgA1 production down 50% at week 96
+ Proteinuria (UPCR) reduced by 55.2% at week 96
This is at week 96, 18 *months* after treatment was discontinued at week 24. #NephSky #KidneyWk #IgAN #IgANephropathy
Treatment of patients with #IgAnephropathy: a call for a new paradigm
doi.org/10.1016/j.kint.2025.01.014
#OpenAccess #NephSky #MedSky #SkyNeph #IgAN #KIReview #kidneydisease
doi.org/10.1016/j.kint.2025.01.014
#OpenAccess #NephSky #MedSky #SkyNeph #IgAN #KIReview #kidneydisease
April 29, 2025 at 7:51 PM
Treatment of patients with #IgAnephropathy: a call for a new paradigm
doi.org/10.1016/j.kint.2025.01.014
#OpenAccess #NephSky #MedSky #SkyNeph #IgAN #KIReview #kidneydisease
doi.org/10.1016/j.kint.2025.01.014
#OpenAccess #NephSky #MedSky #SkyNeph #IgAN #KIReview #kidneydisease
ISN-KDIGO Webinar Series on #Complement in #GN – What is new in the management of #IgANephropathy.
#kdigo #theisn #isneducation #isnkidneycare #glomerulonephritis
With Dr. VIVEKANANDA JHA, DR. HEATHER REICH, DR. MARINA VIVARELLI @vjha126
#kdigo #theisn #isneducation #isnkidneycare #glomerulonephritis
With Dr. VIVEKANANDA JHA, DR. HEATHER REICH, DR. MARINA VIVARELLI @vjha126
March 28, 2025 at 3:12 AM
ISN-KDIGO Webinar Series on #Complement in #GN – What is new in the management of #IgANephropathy.
#kdigo #theisn #isneducation #isnkidneycare #glomerulonephritis
With Dr. VIVEKANANDA JHA, DR. HEATHER REICH, DR. MARINA VIVARELLI @vjha126
#kdigo #theisn #isneducation #isnkidneycare #glomerulonephritis
With Dr. VIVEKANANDA JHA, DR. HEATHER REICH, DR. MARINA VIVARELLI @vjha126
A study examined the use of #Nefecon, a targeted-release #budesonide formulation, in patients with #IgAN and severe renal impairment. #iganephropathy #nephrology #nephsky www.docwirenews.com/post/targete...
Targeted-Release Budesonide Shows Benefit for Patients With Severe Renal Impairment | Docwire News
Nefecon, a targeted-release form of budesonide, can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgA nephropathy (IgAN), a study found.
www.docwirenews.com
June 9, 2025 at 3:31 PM
A study examined the use of #Nefecon, a targeted-release #budesonide formulation, in patients with #IgAN and severe renal impairment. #iganephropathy #nephrology #nephsky www.docwirenews.com/post/targete...
Loin pain is common among patients with IgAN but little is reported about its impact on quality of life or management strategies. #kidneywk #iganephropathy #loinpain #nephsky
Loin Pain in Patients With IgAN | Docwire News
A study examined the impact loin pain has on IgA nephropathy (IgAN) patients' quality of life and strategies to manage the pain.
buff.ly
December 13, 2024 at 10:00 PM
Loin pain is common among patients with IgAN but little is reported about its impact on quality of life or management strategies. #kidneywk #iganephropathy #loinpain #nephsky
🎭🔫🗡️🌹We can't take the drama away from #IgANephropathy.. bring in those commited #complement warriors🔫🗡️⚠️🗝️
x.com/NDTsocial/stat…
x.com/NDTsocial/stat…
March 28, 2025 at 3:44 AM
🎭🔫🗡️🌹We can't take the drama away from #IgANephropathy.. bring in those commited #complement warriors🔫🗡️⚠️🗝️
x.com/NDTsocial/stat…
x.com/NDTsocial/stat…
Dr. Richard Lafayette discussed the FDA's accelerated approval of atrasentan in IgAN and supporting results from the ALIGN study. #nephsky #nephrology #iganephropathy #igan www.docwirenews.com/post/acceler...
Accelerated Approval for Atrasentan in IgAN | Docwire News
Nephrology Times spoke with ALIGN study investigator Richard Lafayette, MD, of Stanford, upon the FDA's accelerated approval of atrasentan for IgA nephropathy (IgAN).
www.docwirenews.com
May 1, 2025 at 1:52 PM
Dr. Richard Lafayette discussed the FDA's accelerated approval of atrasentan in IgAN and supporting results from the ALIGN study. #nephsky #nephrology #iganephropathy #igan www.docwirenews.com/post/acceler...
shoutout to my immune system for choosing violence and turning my kidneys into a slow-burn tragedy.
every pee is a suspense thriller now.
#IGANephropathy #AutoimmuneAF #PissingInFear
every pee is a suspense thriller now.
#IGANephropathy #AutoimmuneAF #PissingInFear
June 22, 2025 at 6:17 AM
shoutout to my immune system for choosing violence and turning my kidneys into a slow-burn tragedy.
every pee is a suspense thriller now.
#IGANephropathy #AutoimmuneAF #PissingInFear
every pee is a suspense thriller now.
#IGANephropathy #AutoimmuneAF #PissingInFear
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found. #infliximab #igan #iganephropathy #crohns #nephrology #nephsky www.docwirenews.com/post/case-st...
Case Studies Highlight Link Between Crohn’s Disease Treatment and IgAN | Docwire News
Infliximab therapy for Crohn’s disease is linked to a high risk for IgA nephropathy (IgAN), a study found.
www.docwirenews.com
June 25, 2025 at 4:31 PM
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found. #infliximab #igan #iganephropathy #crohns #nephrology #nephsky www.docwirenews.com/post/case-st...
The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and #IgAN. #nephrology #skindisease #iganephropathy #nephsky
Association Between Inflammatory Skin Diseases and IgA Nephropathy | Docwire News
A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases, such as atopic dermatitis, acne, and psoriasis.
buff.ly
December 14, 2024 at 4:05 PM
The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and #IgAN. #nephrology #skindisease #iganephropathy #nephsky
Expanding the spectrum of genetic causes of DNA-specific exonucleaseTREX1 variants in thrombotic microangiopathy
doi.org/10.1016/j.kint.2025.04.014
#MedSky #NephSky #IgAN #IgANephropathy
doi.org/10.1016/j.kint.2025.04.014
#MedSky #NephSky #IgAN #IgANephropathy
May 19, 2025 at 3:49 PM
Expanding the spectrum of genetic causes of DNA-specific exonucleaseTREX1 variants in thrombotic microangiopathy
doi.org/10.1016/j.kint.2025.04.014
#MedSky #NephSky #IgAN #IgANephropathy
doi.org/10.1016/j.kint.2025.04.014
#MedSky #NephSky #IgAN #IgANephropathy
Monthly REMS labs are tomorrow. Why do I get nervous every single blood draw? #IgANephropathy #IgAN #kidneydisease
May 18, 2025 at 2:40 PM
Monthly REMS labs are tomorrow. Why do I get nervous every single blood draw? #IgANephropathy #IgAN #kidneydisease
How did the COVID-19 pandemic affect the incidence and pathology of IgAN? #iganephropathy #covid #nephsky #nephrology #kidneydisease
Changes in IgAN Incidence and Pathology During the COVID-19 Pandemic | Docwire News
A systematic evaluation compared the incidence of IgA nephropathy (IgAN) and changes in its pathology before and during the COVID-19 pandemic.
buff.ly
March 5, 2025 at 5:50 PM
How did the COVID-19 pandemic affect the incidence and pathology of IgAN? #iganephropathy #covid #nephsky #nephrology #kidneydisease